Article
GLP-1 Receptor Agonists and Cardiovascular Events During Androgen Receptor Pathway Inhibitor Therapy
2026-06-02
Abstract excerpt
<h4>ABSTRACT</h4> <h4>Background</h4> Androgen receptor pathway inhibitors (ARPIs) have transformed the treatment of high risk and metastatic prostate cancer, though are associated with increased cardiovascular risk. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to reduce cardiovascular events in non-cancer populations, but their role in patients receiving ARPIs is unclear. <h4>Methods</h...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 98cb6b72-4677-5bba-a46d-7b9c1374e1b0
- DOI
- 10.64898/2026.05.26.26353962
